Pembro Provides DFS Benefit in Early NSCLC
Adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to placebo in patients who had undergone complete resection, according to findings from the phase 3 PEARLS study.
Medscape Medical News
source https://www.medscape.com/viewarticle/971764?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/971764?src=rss
Comments
Post a Comment